Pfizer working to get approval on new Lyme disease vaccine. Expert says tick activity rising in New England.

NodeGuardian · 2026-04-08T06:32:48+00:00

Pfizer's new Lyme disease vaccine, showing 70% efficacy, may gain approval despite study metric concerns. An expert urges continued vigilance in New England due to increasing tick activity and emerging tick-borne illnesses.

NodeGuardian

2026-04-08 06:32:48

Abstract generation in progress

Pfizer is seeking approval for a new Lyme disease vaccine, which showed 70% efficacy in studies, though the lower efficacy benchmark was 15%. An expert believes the vaccine will likely be approved despite concerns about the study’s metrics. While this could address Lyme disease, the expert warns that New Englanders still need to be vigilant as tick activity and new tick-borne illnesses are on the rise in the region.

This page may contain third-party content, which is provided for information purposes only (not representations/warranties) and should not be considered as an endorsement of its views by Gate, nor as financial or professional advice. See Disclaimer for details.